Home

Public Policy

Ron Cohen, President and CEO, Acorda Therapeutics, Inc.

Dr. Cohen discusses the plight of today’s emerging biotech companies, and how the federal government can best support innovation within the industry.

2011 BIO International Convention Governors Highlight Reel

The 2011 BIO International Convention brought together over 15,000 leaders from industry, government and academia who are working to solve some of the sector's biggest challenges. We were honored to host governors from 11 U.S. states as they promote their bioscience economic development endeavors.

BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Podcast: BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

BIO's 2012 Legislative Priorities - Part II

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations.

2011: A Pivotal Year for Biotechnology

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world.

BIO's 2012 Legislative Priorities

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations. In this two part series, Del Monte discusses the outlook for 2012 and legislative priorities.

New Orleans Biotech Center Drives Job Growth and Diversifies Economy

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The city reached a  milestone its renaissance when the New Orleans BioInnovation Center (NOBIC) opened for business.

Capital Formation Spurs Job Growth

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

Can a 21st Century FDA Accelerate Biotech Innovation to Cure Disease and Save Lives?

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.

How States Can Foster and Expand Biotech Industry Development

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Becoming a Part of the Biotech Industry

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

Capital Conundrum

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

What Do Voters Think About the Biotechnology Industry?

What is your opinion of biotechnology companies – very favorable, somewhat favorable, somewhat unfavorable, or very unfavorable?

BIO Grassroots Handbook

A strong Network will bolster public awareness of the industry and encourage more investment dollars.

Letters, Testimony & Comments

Transatlantic Trade and Investment Partnership
May 16 2013
Introduction The Biotechnology Industry Organization (BIO) appreciates the opportunity to respond to the Request for Comments issued by...
BIO's letter to FL Governor Scott Regarding Substitution of Biosimilar Medicines
May 8 2013
The Honorable Rick Scott Office of the Governor State of Florida 400 S. Monroe St. Tallahassee, FL 32399-0001 Dear Governor Scott...
PBRER: BIO Comments on Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format
May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
Benefit-Risk: BIO Comments on FDA's Prescription Drug User Fee Act V Benefit-Risk Plan
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
More Letters, Testimony & Comments →

Press Releases

BIO Commends Supreme Court's Support for Continued Biotech Innovation
May 14 2013
Washington, D.C. (May 13, 2013) Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO)...
BIO Releases Bioscience Economic Development Report and Guide
April 23 2013
The Biotechnology Industry Organization (BIO) released its “Bioscience Economic Development: Legislative...
BIO Applauds Reps. Hurt and Meeks for Introducing H.R. 1564 to Avoid Burdensome Regulations
April 16 2013
Washington, D.C. (April 16, 2013) Washington, D.C. (April 16, 2013) – The Biotechnology Industry Organization...
Administration’s Budget Proposal Undercuts Development of Cures and Breakthroughs, and Hurts Job Growth
April 11 2013
Washington, D.C. (April 16, 2013) Washington, D.C. (April 16, 2013) – The Biotechnology Industry Organization...
Biosimilars Bill Seeks To Notify Patients & Doctors of Changes to Prescriptions
April 3 2013
Washington, D.C. (April 2, 2013) –  The Biotechnology Industry Organization (BIO) and BioFlorida commend...
More Press Releases →